ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells

Arjan Kol(University Medical Center Groningen), Steven de Jong(University Medical Center Groningen)
Oncotarget
April 17, 2017
Cited by 31


Related Papers